Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New progestogens in oral contraception

K Fotherby1, A D Caldwell

  • 1Royal Postgraduate Medical School, London, UK.

Contraception
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Partial pituitary ablation with implants of gold-198 and yttrium-90 for Cushing's syndrome with associated adrenal hyperplasia.

British medical journal·2010
Same author

Can a change in screening and prescribing practice reduce the risk of venous thromboembolism in women taking the combined oral contraceptive pill?

The British journal of family planning·1999
Same author

Recommendations for clinical practice: actinomyces like organisms and intrauterine contraceptives. The Clinical and Scientific Committee.

The British journal of family planning·1999
Same author

Metabolic interrelationships, cardiovascular disease, and sex steroids.

Contraception·1998
Same author

Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy.

Contraception·1996
Same author

Guidelines for prescribing combined oral contraceptives.

BMJ (Clinical research ed.)·1996

Newer combined oral contraceptives (COCs) offer improved pharmacological profiles compared to older formulations. While older low-dose COCs remain safe, newer options demonstrate clinical acceptance and efficacy.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Gynecology

Background:

  • Combined oral contraceptives (COCs) have evolved with reduced estrogen and progestogen doses.
  • Newer progestogens in COCs are marketed for increased selectivity.
  • Previous generations of COCs, particularly low-dose formulations, have a long history of safe use.

Purpose of the Study:

  • To review the clinical efficacy of new COCs.
  • To compare new COCs with older formulations containing levonorgestrel or norethisterone.
  • To evaluate the pharmacological effects of new COCs on metabolic, hematological, and hormonal parameters.

Main Methods:

  • Review of clinical efficacy data for new COCs.
  • Pharmacological assessment of effects on carbohydrate and lipid metabolism.
Keywords:
BiologyCarbohydrate Metabolic EffectsContraceptionContraceptive Agents, Female--pharmacodynamicsContraceptive Agents, Progestin--pharmacodynamicsContraceptive Agents--pharmacodynamicsContraceptive MethodsContraceptive UsageDesogestrel--pharmacodynamicsFamily PlanningGestodene--pharmacodynamicsHematological EffectsHemic SystemLipid Metabolic EffectsLipidsLiterature ReviewMetabolic EffectsMethod AcceptabilityNorgestimate--pharmacodynamicsOral ContraceptivesOral Contraceptives, Low-dosePhysiologySerum Protein Effects

Related Experiment Videos

  • Analysis of impact on hematological factors, pituitary-ovarian function, and serum protein/androgen levels.

    • Main Results:

    • Newer COCs show pharmacological improvements over older low-dose formulations.
    • Newer COCs are preferable to high-dose formulations based on pharmacological evidence.
    • Older low-dose COCs exhibit a low incidence of adverse effects despite prolonged use.

    Conclusions:

    • Newer combined oral contraceptives represent an advancement over older formulations.
    • The clinical acceptance and increasing market share of new COCs indicate positive reception.
    • Both older low-dose and newer COCs have established roles, with newer options offering pharmacological benefits.